Compare AbCellera Biologics Inc (ABCL) vs STMicroelectronics NV (STM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs STMicroelectronics NV — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while STMicroelectronics NV trades at $68.62 (market cap $59.25B). The key difference: STMicroelectronics NV is far larger — about 25.2× AbCellera Biologics Inc's market cap, and STMicroelectronics NV pays a 0.54% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | STM | |
|---|---|---|
Market Cap | $2.35B | $59.25B |
Sector | Health | Financials |
52-Week High | $8.12 | $79.91 |
52-Week Low | $2.78 | $21.20 |
Enterprise Value | $1.99B | $57.46B |
Dividend Yield | — | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
STM trades at $67.28, down 1.57% today, with a neutral technical signal and mixed earnings history. The company shows strong cash flow from operations at $2.15B in 2025 and maintains a solid balance sheet with $6.18B cash. Recent news highlights growth in AI, automotive, and industrial segments, including new product launches like the VL53L9 LiDAR module. Analyst consensus is a Buy with a $72.33 price target, indicating potential upside from current levels.
Outlook is cautiously optimistic given STM's strategic positioning in high-growth semiconductor markets, but high valuation ratios (P/E 446.19) and recent earnings misses pose risks. Revenue decline from $17.3B in 2023 to $11.8B in 2025 requires monitoring, though cost control and innovation in edge AI and automotive chips offer long-term opportunities amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
